In whatever form biosimilar legislation might take, patent holders will need to review their patent portfolios carefully
Sanya Sukduang
Advertisement
Articles by Sanya Sukduang
Advertisement
Latest Updated Articles
- Follow-on Biologics: A Patent Litigation Perspective
Published: August 22nd 2009 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Lilly Agreement With Trump Administration Reshapes Patient Access to GLP-1 Obesity Medicines
2
Mark Cuban Cost Plus Drug Company Adds Starjemza to Prescription Drug Portfolio
3
Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?
4
